{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:22:04Z","timestamp":1783430524946,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jad.2021.02.048","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T17:56:52Z","timestamp":1614016612000},"page":"120-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Population pharmacokinetic\/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation"],"prefix":"10.1016","volume":"285","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-7351","authenticated-orcid":false,"given":"Yun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.02.048_bib0002","unstructured":"U.S. FDA., 2012. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses."},{"key":"10.1016\/j.jad.2021.02.048_bib0003","unstructured":"Medicines and Healthcare products Regulatory Agency., 2014. Citalopram and escitalopram: QT interval prolongation-New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Published 11 December 2014. Medicines and Healthcare products Regulatory Agency."},{"key":"10.1016\/j.jad.2021.02.048_bib0007","unstructured":"Health Canada., 2012. Antidepressant cipralex (escitalopram): updated information regarding dose-related heart risk."},{"key":"10.1016\/j.jad.2021.02.048_bib0001","unstructured":"Allergan USA, Inc. Lexapro\u00ae (escitalopram oxalate) [Prescribing Information]. 2017. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021323s047lbl.pdf (accessed on December 2019)."},{"key":"10.1016\/j.jad.2021.02.048_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10928-015-9457-6","article-title":"A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer\u2019s disease patients with agitation","volume":"43","author":"Akil","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jad.2021.02.048_bib0005","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1208\/aapsj080102","article-title":"The pharmacokinetics of escitalopram in patients with hepatic impairment","volume":"8","author":"Areberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.jad.2021.02.048_bib0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1460-9592.2003.00053.x","article-title":"Circadian profile of QT interval and QT interval variability in 172 healthy volunteers","volume":"26","author":"Bonnemeier","year":"2003","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.jad.2021.02.048_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-013-0911-y","article-title":"Escitalopram block of hERG potassium channels","volume":"387","author":"Chae","year":"2014","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/clpt.2011.202","article-title":"Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development","volume":"90","author":"Chain","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2021.02.048_bib0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40262-014-0162-1","article-title":"Impact of cytochrome P450 2C19 polymorphisms on citalopram\/escitalopram exposure: a systematic review and meta-analysis","volume":"53","author":"Chang","year":"2014","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.jad.2021.02.048_bib0011","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/bcp.13994","article-title":"Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment","volume":"85","author":"Courlet","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jad.2019.02.060","article-title":"Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting","volume":"250","author":"Crepeau-Gendron","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.02.048_bib0013","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41569-019-0167-4","article-title":"Circadian rhythms and the molecular clock in cardiovascular biology and disease","volume":"16","author":"Crnko","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jad.2021.02.048_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11095-015-1760-9","article-title":"Assessment of interspecies differences in drug-induced QTc interval prolongation in cynomolgus monkeys, dogs and humans","volume":"33","author":"Dubois","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jad.2021.02.048_bib0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00392-017-1152-8","article-title":"Circadian rhythm of blood cardiac troponin T concentration","volume":"106","author":"Fournier","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.jad.2021.02.048_bib0016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11204760-000000000-00000","article-title":"Escitalopram: a review of its use in the management of major depressive disorder in adults","volume":"24","author":"Garnock-Jones","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2021.02.048_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10543406.2010.539309","article-title":"Delayed effects in the exposure-response analysis of clinical QTc trials","volume":"22","author":"Glomb","year":"2012","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.jad.2021.02.048_bib0018","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1981.tb01123.x","article-title":"The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration\u2013effect relationships","volume":"11","author":"Holford","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature10852","article-title":"Circadian rhythms govern cardiac repolarization and arrhythmogenesis","volume":"483","author":"Jeyaraj","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jad.2021.02.048_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0091270009337946","article-title":"Effect of age, weight, and CYP2C19 genotype on escitalopram exposure","volume":"50","author":"Jin","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0021","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/psp4.12085","article-title":"Levofloxacin-induced QTc prolongation depends on the time of drug administration","volume":"5","author":"Kervezee","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YIC.0000000000000124","article-title":"A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers","volume":"31","author":"Kim","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0023","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.clpt.6100089","article-title":"Thorough QT study with recommended and supratherapeutic doses of tolterodine","volume":"81","author":"Malhotra","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2021.02.048_bib0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-200124050-00001","article-title":"Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling","volume":"24","author":"Malik","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2021.02.048_bib0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10928-018-9587-8","article-title":"Importance of QT\/RR hysteresis correction in studies of drug-induced QTc interval changes","volume":"45","author":"Malik","year":"2018","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.jad.2021.02.048_bib0026","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1023\/A:1014460404352","article-title":"Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic\/pharmacodynamic model incorporating a site of adverse effect","volume":"28","author":"Minematsu","year":"2001","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.jad.2021.02.048_bib0027","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.ehj.2004.08.020","article-title":"Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome","volume":"25","author":"Noda","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jad.2021.02.048_bib0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5455\/bcp.20140304090654","article-title":"Escitalopram-induced bradycardia in elderly individuals: a case series report","volume":"25","author":"Ozdilek","year":"2015","journal-title":"Klin Psikofarmakol B"},{"key":"10.1016\/j.jad.2021.02.048_bib0029","doi-asserted-by":"crossref","DOI":"10.1208\/aapsj070363","article-title":"Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT\/QTc prolongation","volume":"7","author":"Piotrovsky","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.jad.2021.02.048_bib0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2021.02.048_bib0031","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jad.2021.02.048_bib0032","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00392-003-0936-1","article-title":"[Circadian rhythm of QT- and QTc-intervals in diabetics and hypertensives]","volume":"92","author":"Seyfert","year":"2003","journal-title":"Z. Kardiol."},{"key":"10.1016\/j.jad.2021.02.048_bib0033","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2002.01627.x","article-title":"The significance of QT interval in drug development","volume":"54","author":"Shah","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0034","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/cap.2018.0160","article-title":"CYP2C19-Guided escitalopram and sertraline dosing in pediatric patients: a pharmacokinetic modeling study","volume":"29","author":"Strawn","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0035","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pds.3289","article-title":"Removal from labeling of 60-mg citalopram dose","volume":"21","author":"Temple","year":"2012","journal-title":"Pharmacoepidem Dr S"},{"key":"10.1016\/j.jad.2021.02.048_bib0036","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10543400801995502","article-title":"Statistical issues of QT prolongation assessment based on linear concentration modeling","volume":"18","author":"Tsong","year":"2008","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.jad.2021.02.048_bib0037","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.2011.04091.x","article-title":"Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal","volume":"73","author":"van Gorp","year":"2012","journal-title":"Br. J. Clin. Pharmaco"},{"key":"10.1016\/j.jad.2021.02.048_bib0038","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.1980.tb04799.x","article-title":"Quantitative analysis of the disopyramide concentration-effect relationship","volume":"9","author":"Whiting","year":"1980","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2021.02.048_bib0039","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/01.CIR.0000058752.79734.F0","article-title":"Circadian variation of cardiac K+ channel gene expression","volume":"107","author":"Yamashita","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jad.2021.02.048_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000063568","article-title":"Twenty-four-hour QT interval variability: increased QT variability during sleep in patients with panic disorder","volume":"46","author":"Yeragani","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2021.02.048_bib0041","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.clinthera.2017.05.349","article-title":"Population pharmacokinetic\/pharmacodynamics modeling of ibutilide in Chinese healthy volunteers and patients with atrial fibrillation (AF) and\/or atrial flutter (AFL)","volume":"39","author":"Zeng","year":"2017","journal-title":"Clin. Ther."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:53:45Z","timestamp":1759024425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"alternative-id":["S0165032721001749"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.02.048","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic\/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}